EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company centered on producing and commercializing vaccines, nowadays introduced that Kelly MacDonald has been appointed Senior Vice President and Chief Economic Officer. Ms. MacDonald will join the organization powerful March 1, 2021.
As beforehand declared, immediately after 14 yrs at Dynavax, Chief Fiscal Officer Michael Ostrach is retiring. Mr. Ostrach has agreed to stay available as an advisor to the Company thereafter.
“Michael’s contributions and unwavering determination to Dynavax have been important to the results of our enterprise. We are exceptionally fortuitous to have had his advice about the decades and now as a strategic advisor to be certain a seamless changeover to his successor,” commented Ryan Spencer, Chief Govt Officer of Dynavax. “Kelly is an accomplished fiscal leader with a deep knowing of company and professional finance and will be an asset as we improve our organization of creating vaccines to assist stop the unfold of infectious conditions. On behalf of the board and the other members of the govt workforce, it is a pleasure to welcome Kelly to Dynavax.”
“This is an interesting time to be part of Dynavax as it proceeds to construct a main vaccine enterprise, addressing urgent international health and fitness needs,” commented Kelly MacDonald. “I share the long-expression motivation to Dynavax’ eyesight of collaboration, innovation and progress and appear forward to primary the finance and accounting staff in executing the company’s strategic and financial aims.”
Ms. MacDonald joins Dynavax from Ironwood Prescription drugs exactly where she held roles of escalating obligation. In her last position at Ironwood Ms. MacDonald served as Main Accounting Officer and Vice President, Finance where she led the Company’s corporate accounting and finance procedures, company risk administration, treasury and cash allocation method. Whilst at Ironwood, she also held a variety of other managerial roles, offering finance and accounting help for the company’s strategic arranging, R&D portfolio administration, world business enterprise advancement, products launches and professional execution. Prior to joining Ironwood, Kelly was a Supervisor in the Health and fitness Industries Assurance Follow at PricewaterhouseCoopers, principally serving clients in everyday living sciences and technology sectors.
Ms. MacDonald is a Licensed Public Accountant (CPA) and retains a Master of Organization Administration from the Isenberg School of Management at the College of Massachusetts and a Bachelor of Science in Accounting from Fairfield College.
Dynavax is a business phase biopharmaceutical corporation building and commercializing novel vaccines. The Company’s first commercial solution, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of an infection triggered by all acknowledged subtypes of hepatitis B virus in older people age 18 yrs and more mature. Dynavax is also advancing CpG 1018 as a leading vaccine adjuvant by means of study collaborations and partnerships. Present-day collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and common influenza. For additional data, visit www.dynavax.com and abide by the organization on LinkedIn.
Nicole Arndt, Senior Supervisor, Trader Relations
Derek Cole, President
Investor Relations Advisory Options
Look at authentic material to download multimedia: http://www.prnewswire.com/news-releases/dynavax-appoints-kelly-macdonald-as-chief-economical-officer-301211428.html
Resource Dynavax Systems